Pressure BioSciences Inc. (PBIO) Enters Contract S
Post# of 1354
(Total Views: 176)
Posted On: 08/13/2019 4:44:14 PM
Pressure BioSciences Inc. (PBIO) Enters Contract Services Agreement with World-Renowned Biotherapeutics Firm
- PBIO expects to achieve a significant revenue increase in 2019 and beyond through the expansion of its proprietary BaroFold platform into the estimated $44 billion global bioprocess technology market
- Over 200 therapeutic proteins and peptides are currently approved by the FDA for use with conditions such as cancer, immunological and metabolic disorders and infectious diseases
- Hundreds of additional protein and peptide-based drugs are in development worldwide
- PBIO’s proprietary BaroFold platform offers a unique and cost-effective way to address two of the most complex and challenging issues critical to the development and manufacture of therapeutic proteins
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based technologies and products to the worldwide life sciences and other industries, recently announced its execution of a contract services agreement with a world-renowned, multibillion-dollar biotherapeutics firm. Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://nnw.fm/n6GTk).
PBIO’s BaroFold technology platform offers a unique and cost-effective way to address the complex and often challenging process of manufacturing the recombinant proteins that are required in the development of protein-based drugs. Two of the major challenges associated with manufacturing recombinant proteins are (1) the formation of aggregates and (2) protein misfolding. These are significant issues that can prevent a protein drug candidate from ever making it to market.
“The BaroFold platform can be applied to the development and production of many different therapeutic proteins, can improve product safety, and is scalable and practical for standard bioprocess environments,” Dr. Alexander Lazarev, PBIO’s chief science officer, stated in a news release. “Moreover, it offers ways to reduce or eliminate the use of aggressive chemicals in the protein manufacturing process. We believe this unique technology platform can help biopharmaceutical companies create and manufacture high quality novel protein therapeutics and biosimilars, lower the cost of existing formulations, and help protect our environment.”
Protein-based therapeutics are a large and growing part of the global health care industry. Based on data in the THPdb database (http://nnw.fm/gLO96), there are over 200 therapeutic proteins and peptides currently approved by the FDA for clinical use in the United States. These target therapies have shown significantly improved outcomes for many patients suffering from severe medical conditions, such as cancer and immunological diseases. The global protein drug market is projected to reach nearly $249 billion by 2020 at a compound annual growth rate of 7.3 percent from 2015 to 2020, according to data from Research and Markets (http://nnw.fm/d0TDj).
PBIO’s recently launched Biopharma Services Business – based on its patented BaroFold technology platform – also provides the company with a unique opportunity to enter the global bioprocess technology market, which Transparency Market Research expects to be valued at an estimated $44 billion by 2026 (http://nnw.fm/g0UmN).
“In addition to successfully performing contract services for two biopharmaceutical companies since the beginning of 2019, we are also in discussions with three additional bio-therapeutic companies interested in utilizing our proprietary BaroFold services for their protein drug candidates,” Richard T. Schumacher, president and CEO of PBIO, stated in a news release. “To take full advantage of this opportunity, we have doubled the capacity of our contract services team, purchased additional sophisticated equipment, and developed new high-pressure concepts that further improve and enhance our BaroFold process scalability and its GMP compliance.”
“We believe our recently launched Biopharma Services Business could add as much as $500,000 to 2019 total revenue and significantly more to total revenue for 2020 and beyond,” Schumacher concluded. “It is important to note that these estimates do not include the anticipated growth in Barocycler 2320EXT sales that we believe will result from biotechnology and biopharmaceutical companies developing their own manufacturing, quality control, and protein characterization applications on our leading PCT-based instrument system.”
In addition to its new Biopharma Services Business, the company develops and markets high-pressure instruments for scientific research purposes throughout the United States, Canada, Europe, Australia and Asia. To date, PBIO has installed approximately 350 pressure cycling technology (PCT) systems (Barocycler, Barozyme, HUB) in nearly 200 leading academic, government, biotech and pharma laboratories around the world, while its PCT platform continues to be prominently featured in a record number of international science conferences (http://nnw.fm/k2wZr).
The company recently announced that it will be entering the rapidly growing CBD market with its newly designed BaroShear K45 instrument. Based on its proprietary Ultra Shear Technology (UST) platform, the company believes that BaroShear K45 sales in 2020 will result in a doubling of current 2019 revenue. Besides the CBD market, this revolutionary processing system is also expected to attract customers spanning multiple markets, including pharmaceuticals, cosmetics, nutraceuticals, food and beverage, and more.
For more information, visit the company’s website at www.PressureBioSciences.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- PBIO expects to achieve a significant revenue increase in 2019 and beyond through the expansion of its proprietary BaroFold platform into the estimated $44 billion global bioprocess technology market
- Over 200 therapeutic proteins and peptides are currently approved by the FDA for use with conditions such as cancer, immunological and metabolic disorders and infectious diseases
- Hundreds of additional protein and peptide-based drugs are in development worldwide
- PBIO’s proprietary BaroFold platform offers a unique and cost-effective way to address two of the most complex and challenging issues critical to the development and manufacture of therapeutic proteins
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based technologies and products to the worldwide life sciences and other industries, recently announced its execution of a contract services agreement with a world-renowned, multibillion-dollar biotherapeutics firm. Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://nnw.fm/n6GTk).
PBIO’s BaroFold technology platform offers a unique and cost-effective way to address the complex and often challenging process of manufacturing the recombinant proteins that are required in the development of protein-based drugs. Two of the major challenges associated with manufacturing recombinant proteins are (1) the formation of aggregates and (2) protein misfolding. These are significant issues that can prevent a protein drug candidate from ever making it to market.
“The BaroFold platform can be applied to the development and production of many different therapeutic proteins, can improve product safety, and is scalable and practical for standard bioprocess environments,” Dr. Alexander Lazarev, PBIO’s chief science officer, stated in a news release. “Moreover, it offers ways to reduce or eliminate the use of aggressive chemicals in the protein manufacturing process. We believe this unique technology platform can help biopharmaceutical companies create and manufacture high quality novel protein therapeutics and biosimilars, lower the cost of existing formulations, and help protect our environment.”
Protein-based therapeutics are a large and growing part of the global health care industry. Based on data in the THPdb database (http://nnw.fm/gLO96), there are over 200 therapeutic proteins and peptides currently approved by the FDA for clinical use in the United States. These target therapies have shown significantly improved outcomes for many patients suffering from severe medical conditions, such as cancer and immunological diseases. The global protein drug market is projected to reach nearly $249 billion by 2020 at a compound annual growth rate of 7.3 percent from 2015 to 2020, according to data from Research and Markets (http://nnw.fm/d0TDj).
PBIO’s recently launched Biopharma Services Business – based on its patented BaroFold technology platform – also provides the company with a unique opportunity to enter the global bioprocess technology market, which Transparency Market Research expects to be valued at an estimated $44 billion by 2026 (http://nnw.fm/g0UmN).
“In addition to successfully performing contract services for two biopharmaceutical companies since the beginning of 2019, we are also in discussions with three additional bio-therapeutic companies interested in utilizing our proprietary BaroFold services for their protein drug candidates,” Richard T. Schumacher, president and CEO of PBIO, stated in a news release. “To take full advantage of this opportunity, we have doubled the capacity of our contract services team, purchased additional sophisticated equipment, and developed new high-pressure concepts that further improve and enhance our BaroFold process scalability and its GMP compliance.”
“We believe our recently launched Biopharma Services Business could add as much as $500,000 to 2019 total revenue and significantly more to total revenue for 2020 and beyond,” Schumacher concluded. “It is important to note that these estimates do not include the anticipated growth in Barocycler 2320EXT sales that we believe will result from biotechnology and biopharmaceutical companies developing their own manufacturing, quality control, and protein characterization applications on our leading PCT-based instrument system.”
In addition to its new Biopharma Services Business, the company develops and markets high-pressure instruments for scientific research purposes throughout the United States, Canada, Europe, Australia and Asia. To date, PBIO has installed approximately 350 pressure cycling technology (PCT) systems (Barocycler, Barozyme, HUB) in nearly 200 leading academic, government, biotech and pharma laboratories around the world, while its PCT platform continues to be prominently featured in a record number of international science conferences (http://nnw.fm/k2wZr).
The company recently announced that it will be entering the rapidly growing CBD market with its newly designed BaroShear K45 instrument. Based on its proprietary Ultra Shear Technology (UST) platform, the company believes that BaroShear K45 sales in 2020 will result in a doubling of current 2019 revenue. Besides the CBD market, this revolutionary processing system is also expected to attract customers spanning multiple markets, including pharmaceuticals, cosmetics, nutraceuticals, food and beverage, and more.
For more information, visit the company’s website at www.PressureBioSciences.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼